Purification and Characterization of the Soluble form of the Receptor for Advanced Glycation End-Products (sRAGE): A Novel Fast, Economical and Convenient Method

Abstract

The receptor for advanced glycation end-products (RAGE) is a multi-ligand receptor which belongs to the pattern recognition receptor family and can bind to various ligands such as advanced glycation end-products (AGEs), members of the S100 protein family, glycosaminoglycans, amyloid β peptides, high-mobility group box-1 (HMGB1) and nucleic acids through its extracellular domain. The RAGE-ligand interaction leads to the activation of MAP kinase and NF-kB signaling pathways. Further ligand-induced up-regulation of RAGE is involved in various patho-physiological situations including late diabetic complications, Alzheimer disease and several other neurodegenerative diseases. A secreted soluble isoform of RAGE (sRAGE), corresponding to the extracellular domain only, has the ability to block RAGE-associated cellular activation and signaling. Further application of recombinant sRAGE has been shown to block RAGE-mediated pathophysiological conditions in various models of cancer or multiple sclerosis. These finding demonstrates sRAGE as a therapeutic tool to block RAGE-associated inflammatory signaling. In this manuscript, we describe a two-step simple, novel and convenient method for expressing and purifying scalable quantities of biologically active murine form of sRAGE by using E.coli as an expression host. The method we propose has several advantages over the current available methods particularly in terms of yield and quality of preparation. The sRAGE produced by this expression system retains all the secondary structural properties as analyzed by the ligand binding affinities. The produced protein also retains all the DNA-RAGE binding functional properties and thus can be a valuable tool for studying dynamics of this novel RAGE ligand. Moreover this method can be utilized by researchers to generate biologically active endotoxin-free sRAGE for in vivo applications to study and treat RAGE-associated pathologies.

^* equally contributed to this work

• References

• 1 Schmidt AM, Yan SD, Yan SF. et al. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 2001; 108: 949-955
• 2 Chavakis T, Bierhaus A, Nawroth PP. RAGE (receptor for advanced glycation end products): A central player in the inflammatory response. Microbes Infect 2004; 6: 1219-1225
• 3 Du Yan S, Zhu H, Fu J. et al. Amyloid-beta peptide-receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: A proinflammatory pathway in Alzheimer disease. Proc Natl Acad Sci USA 1997; 94: 5296-5301
• 4 Englert JM, Hanford LE, Kaminski N. et al. A role for the receptor for advanced glycation end products in idiopathic pulmonary fibrosis. Am J Pathol 2008; 172: 583-591
• 5 Bierhaus A, Humpert PM, Morcos M. et al. Understanding RAGE, the receptor for advanced glycation end products. J Mol Med (Berl) 2005; 83: 876-886
• 6 McVicar CM, Ward M, Colhoun LM. et al. Role of the receptor for advanced glycation endproducts (RAGE) in retinal vasodegenerative pathology during diabetes in mice. Diabetologia 2015; 58: 1129-1137
• 7 Haslbeck KM, Schleicher E, Bierhaus A. et al. The AGE/RAGE/NF-(kappa)B pathway may contribute to the pathogenesis of polyneuropathy in impaired glucose tolerance (IGT). Exp Clin Endocrinol Diabetes 2005; 113: 288-291
• 8 Park L, Raman KG, Lee KJ. et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 1998; 4: 1025-1031
• 9 von Bauer R, Oikonomou D, Sulaj A. et al. CD166/ALCAM mediates proinflammatory effects of S100B in delayed type hypersensitivity. J Immunol 2013; 191: 369-377
• 10 Goova MT, Li J, Kislinger T. et al. Blockade of receptor for advanced glycation end-products restores effective wound healing in diabetic mice. Am J Pathol 2001; 159: 513-525
• 11 Bierhaus A, Nawroth PP. Multiple levels of regulation determine the role of the receptor for AGE (RAGE) as common soil in inflammation, immune responses and diabetes mellitus and its complications. Diabetologia 2009; 52: 2251-2263
• 12 Bopp C, Bierhaus A, Hofer S. et al. Bench-to-bedside review: The inflammation-perpetuating pattern-recognition receptor RAGE as a therapeutic target in sepsis. Crit Care 2008; 12: 201
• 13 Rudofsky Jr. G, Isermann B, Schilling T. et al. A 63 bp deletion in the promoter of rage correlates with a decreased risk for nephropathy in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes 2004; 112: 135-141
• 14 Englert JM, Ramsgaard L, Valnickova Z. et al. Large scale isolation and purification of soluble RAGE from lung tissue. Protein Expr Purif 2008; 61: 99-101
• 15 Bierhaus A, Stern DM, Nawroth PP. RAGE in inflammation: a new therapeutic target?. Curr Opin Investig Drugs 2006; 7: 985-991
• 16 Wilton R, Yousef MA, Saxena P. et al. Expression and purification of recombinant human receptor for advanced glycation endproducts in Escherichia coli. Protein Expr Purif 2006; 47: 25-35
• 17 Ostendorp T, Weibel M, Leclerc E. et al. Expression and purification of the soluble isoform of human receptor for advanced glycation end products (sRAGE) from Pichia pastoris. Biochem Biophys Res Commun 2006; 347: 4-11
• 18 Degani G, Colzani M, Tettamanzi A. et al. An improved expression system for the VC1 ligand binding domain of the receptor for advanced glycation end products in Pichia pastoris. Protein Expr Purif 2015; 114: 48-57
• 19 Harper S, Speicher DW. Purification of proteins fused to glutathione S-transferase. Methods Mol Biol 2011; 681: 259-280
• 20 Schmidt AM, Yan SD, Yan SF. et al. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. The Journal of Clinical Investigation 2001; 108: 949-955
• 21 Thornalley PJ, Battah S, Ahmed N. et al. Quantitative screening of advanced glycation endproducts in cellular and extracellular proteins by tandem mass spectrometry. The Biochemical Journal 2003; 375 Pt 3 581-592
• 22 Rebane R, Oldekop ML, Herodes K. Comparison of amino acid derivatization reagents for LC-ESI-MS analysis. Introducing a novel phosphazene-based derivatization reagent. Journal of chromatography B. Analytical technologies in the biomedical and life sciences 2012; 904: 99-106
• 23 Quehenberger P, Bierhaus A, Fasching P. et al. Endothelin 1 transcription is controlled by nuclear factor-kappaB in AGE-stimulated cultured endothelial cells. Diabetes 2000; 49: 1561-1570
• 24 Hofmann MA, Schiekofer S, Kanitz M. et al. Insufficient glycemic control increases nuclear factor-kappa B binding activity in peripheral blood mononuclear cells isolated from patients with type 1 diabetes. Diabetes Care 1998; 21: 1310-1316
• 25 Zhang Y, Liu R, Wu X. The proteolytic systems and heterologous proteins degradation in the methylotrophic yeastPichia pastoris. Annals of Microbiology 2007; 57: 553-560
• 26 Sinha J, Plantz BA, Inan M. et al. Causes of proteolytic degradation of secreted recombinant proteins produced in methylotrophic yeast Pichia pastoris: case study with recombinant ovine interferon-tau. Biotechnology and Bioengineering 2005; 89: 102-112
• 27 Rosano GL, Ceccarelli EA. Recombinant protein expression in Escherichia coli: advances and challenges. Frontiers in Microbiology 2014; 5: 172
• 28 Mogensen JE, Otzen DE. Interactions between folding factors and bacterial outer membrane proteins. Molecular Microbiology 2005; 57: 326-346